Novaferon
Also known as: IFN‑α‑2b‑N, NIFN, Novaferon, Recombinant novel interferon
Source Novaferon at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Novaferon is a recombinant interferon‑alpha‑like protein engineered for enhanced antiviral activity, approved in China for the treatment of COVID‑19 and other viral infections.
Mechanism of Action
Binds IFNAR1/IFNAR2 receptors, activates JAK-STAT signaling, inducing antiviral and immunomodulatory gene expression.
Routes of Administration
Goals & Uses
- Chronic Hepatitis C treatmentAntiviralModerate
- Antitumor activityOncologyLow
- COVID‑19 treatmentAntiviralModerate
- Chronic Hepatitis B treatmentAntiviralModerate
- ImmunomodulationImmunologyLow
- Broad‑spectrum antiviral therapyAntiviralLow
- COVID-19 antiviral therapyAntiviralLow
Contraindications
- Severe autoimmune diseaseImmunologicalModerate
- Severe psychiatric disordersPsychiatricHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe cytopeniasHematologicModerate
- Severe hepatic decompensationHepatic ImpairmentHigh
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Known hypersensitivity to interferon productsAllergyHigh
- Hypersensitivity to interferonsAllergyHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Injection site reactionsLocalCommon
- Neuropsychiatric effectsNeurological / PsychiatricUncommon
- Thyroid dysfunctionEndocrineUncommon
- Flu‑like symptoms (fever, myalgia)SystemicCommon
- MyelosuppressionHematologicCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
Drug Interactions
- Live vaccinesLow
- Zidovudine (AZT)Moderate
- Immunosuppressants (e.g., cyclosporine)Moderate
- RibavirinLow
- TheophyllineModerate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Patients with autoimmune conditionsImmunologicRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveAbsolute
- Elderly patientsAgeRelative
- Pediatric patients (<12 years)PediatricRelative
Regulatory Status
- European UnionUnapprovedNot authorized in EU member states.
- United StatesUnapprovedInvestigational use only.
- United KingdomUnapprovedNo marketing authorization.
Approved for clinical use in China; not approved by FDA, EMA, or MHRA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Novaferon?
Novaferon is a recombinant interferon‑alpha‑like protein engineered for enhanced antiviral activity, approved in China for the treatment of COVID‑19 and other viral infections.
What is Novaferon used for?
Novaferon is educationally associated with: Chronic Hepatitis C treatment, Antitumor activity, COVID‑19 treatment, Chronic Hepatitis B treatment, Immunomodulation, Broad‑spectrum antiviral therapy, COVID-19 antiviral therapy. Educational only — not medical advice.
How is Novaferon administered?
Recorded routes of administration: Inhalation, Intramuscular, Subcutaneous.
What are the potential side effects of Novaferon?
Reported adverse effects include: Flu-like symptoms, Injection site reactions, Neuropsychiatric effects, Thyroid dysfunction, Flu‑like symptoms (fever, myalgia), Myelosuppression, Injection site reaction, Elevated liver enzymes. This list is not exhaustive — consult a qualified clinician.
Who should avoid Novaferon?
Recorded contraindications: Severe autoimmune disease, Severe psychiatric disorders, Pregnancy, Severe cytopenias, Severe hepatic decompensation, Autoimmune hepatitis, Known hypersensitivity to interferon products, Hypersensitivity to interferons. Consult a qualified clinician before use.